Given below are two profiles of NPIL, which give a brief synopsis of the Company in 500 words and 200 words respectively. Please use these as required.

(500 Words)

Nicholas Piramal India Limited (NPIL) is India's second largest Pharmaceutical Healthcare company is a leader in the Cardio-vascular segment. It has a strong presence in Antibiotics and Respiratory segments, Pain management, Neuro-psychiatry and Anti-Diabetics segments. The company is also making forays into Biotechnology in key therapeutic areas for which it has formed several global alliances. For 2005-06, NPIL's recorded a turnover of Rs 14.1 billion and profits after tax were Rs 1.7 billion. 

NPIL's biggest brands in the pharma business are Phensedyl, Ismo, Supradyn, Gardenal, Stemetil, Haemaccel and Rejoint - these bring in 67 per cent of the business, while its secondary brands which include Paraxin, Flagyl and Omnatax contribute around 24 % of its revenues.

An aggressive player in the pharma industry, NPIL came into existence in 1988 when it acquired Nicholas Laboratories from Sara Lee and in the last 15 years grown to its leadership position through a series of well managed acquisitions, mergers and alliances. Some of NPIL's major acquisitions include the Indian operations of Roche Products Ltd., Boehringer Mannheim India Ltd., Hoechst Marrion Roussel Ltd,'s Research Centre, Rhone Poulenc India Ltd., ICI India Ltd.'s Pharma Division and Aventis' Reseach facilities. 

NPIL has joint ventures and alliances with some of the finest global names in the industry which include F. Hoffmann-La Roche Ltd., Switzerland; Allergan Inc., USA; UK; Gilead Sciences, USA; Cheissi, Italy; and IVAX Corp; UK. 

NPIL's core strengths are its 2700-strong field force that offers it the depth and width in the Indian market; successful brand building - today NPIL, together with its JVs, has 16 brands among the top 300 in the Indian Pharma Industry; state-of-the-art manufacturing plants - NPIL's Hyderabad plant is the only one in India to have USFDA approval for the entire facility, it is also accredited and approved by MCA of UK, TGA of Australia and the European and Canadian Drug Authorities, and its Pithampur plant in Central India is accredited by reputed organizations like Allergan, Novartis, Solvay and IVAX, among others, which use it for toll manufacturing.

With the acquisition of Pfizer's Morepeth's manufacturing wite in UK, Nicholas Piramal through its wholly owned subsidiary NPIL Pharmaceuticals Limited, has emerged as one of the leading custom manufacturing organizations across the world.

Today, NPIL, is well poised to take advantage of the opportunities that will emerge in the bulk actives and intermediates market for contract manufacturing at attractive price points of both on patent and off patent drugs for the regulated markets of Europe, US and Japan. The company's track record and credibility in respecting IPR is extremely good and is respected globally. NPIL also has major investments in R&D which focus on formulations development, new chemical entity research, clinical research from laboratories in India and abroad.

NPIL is the flagship company of the Rs. 2500 crore (US $ 500 million) Piramal Enterprises (PEL), one of India's largest diversified business houses. The Group is headed by Mr. Ajay Piramal, who is also the Chairman of NPIL, and among the most respected names in Indian industry.

(200 Words)

Nicholas Piramal India Limited (NPIL) is India's second largest Pharmaceutical and Healthcare company. NPIL is a leader in the Cardio-vascular segment, and has a strong presence in Antibiotics and Respiratory segments, Pain management, Neuro-psychiatry and Anti-Diabetics segments. In 2005-06 its revenues stood at Rs 14.1 billion and PAT at Rs 1.7 billion. 

NPIL which has been in the pharma business for just 15 years, has grown through an aggressive strategy of successfully managed acquisitions, mergers and alliances. NPIL's core strengths are its 2700-strong field force; successful brand building - today 16 of its brands are among the top 300 in the Indian pharma industry; state-of-the-art manufacturing plants - NPIL's Hyderabad plant is the only one in India to have USFDA approval for the entire facility and its unique ability to successfully manage partnerships in the business which is respected globally.NPIL has also emerged as one of the leading custom manufacturing organizations in the world. NPIL also has major investments in R&D within Inia and abroad. which focus on formulations development, new chemical entity research, clinical research. 

NPIL is part of the Rs. 2500 crore (US $ 500 million) Piramal Enterprises (PEL), one of India's largest diversified business houses. The Group is headed by Mr. Ajay Piramal, who is also the Chairman of NPIL.